We are a preclinical drug investment and development platform focused on driving down the cost of drug discovery while advancing therapies into clinical trials.

Pre-Clinical FOCUS

Preclinical development is one of the most attractive areas for healthcare investing today. 

Development Platform

OGB has an investment team as well as an R&D and operations team. 

Investment Capabilities

OGB continues to build close relationships with leading research universities across the country.

 Patient-Centric Mission 

OGB is committed to getting more innovative therapies in the clinic to help patients by working closely with early stage academic researchers through investments in technology.  



Marc Appel

Marc Appel is the CEO of Orange Grove Bio, a biotech platform focused on the investment in and development of preclinical stage assets.

  • Grey LinkedIn Icon
LG Headshot 200103_edited_edited.jpg

Lutz Giebel

Dr. Lutz Giebel, the executive chairman of Orange Grove Bio, a Biotech Entrepreneur based in the San Francisco Bay Area.

  • Grey LinkedIn Icon